Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 3.40 · gapped above the open, then crossed back over prior close. High/low 3.76 at 9:00 am ET, 3.24 at 10:00 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In March 2016, we entered into a license agreement with CIEMAT Group, granting us worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to LVs containing the human PKLR gene solely within the field of treating PKD.”
FILING10-K0001193125-26-076551cik 0001281895
“As of December 31, 2025, the Company has received RP-A501 grants of $5.0 million from CIRM.”
FILING10-K0001193125-26-076551cik 0001281895
“On November 19, 2018, we entered into a license agreement with RGNX, pursuant to which we obtained an exclusive license for all U.S. patents and patent applications related to RGNX's NAV AAV-9 vector for the treatment of DD in humans by in vivo gene therapy using AAV-9 to deliver any known LAMP2 transgene isoforms and all possible combinations of LAMP2 transgene isoforms, as well as an exclusive option to license all U.S. patents and patent applications for two additional NAV AAV vectors.”
FILING10-K0001193125-26-076551cik 0001281895
“On December 1, 2022, we acquired Renovacor, including a license agreement for BAG3 with Temple University.”
FILING10-K0001193125-26-076551cik 0001281895
“In February 2017, we entered into a license agreement with The Regents of the University of California, represented by its San Diego campus, under which UCSD granted us an exclusive, sublicensable, worldwide license to certain intellectual property rights for the treatment of lysosomal storage diseases, including DD.”
FILING10-K0001193125-26-076551cik 0001281895
Watchlist prices, news filtered to it, and its next report on your desk.
Rocket Pharmaceuticals, Inc. has 5 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Rocket Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Rocket Pharmaceuticals, Inc.. Customers appear here when Rocket Pharmaceuticals, Inc. names them, or when a company names Rocket Pharmaceuticals, Inc. as a supplier in its own annual report.
Rocket Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
RCKT (Rocket Pharmaceuticals, Inc.) has 5 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.